Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
| Auteurs principaux: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Publié: |
Elsevier
2019
|
| Résumé: |
|---|